The discovery of BRAF mutations in melanoma and the development of specific BRAF inhibitors has led to significant advances in treatment of metastatic melanoma, which has now been further improved by the use of new immunologic therapy [1]. The gene discussed is BRAF; the disease is metastatic melanoma.